AJMC Biosimilars
3 FOLLOWERS
The American Journal of Managed Care is the leading peer-reviewed journal dedicated to issues in managed care. It distributes healthcare news to leading stakeholders across a variety of platforms. Its Evidence-Based series brings together stakeholder views from payers, providers, policymakers, and pharmaceutical leaders in oncology and diabetes management.
AJMC Biosimilars
1w ago
Through interviews and contributed content, Strategic Alliance Partnerships provide insights into changes in health care delivery and medicine ..read more
AJMC Biosimilars
2M ago
Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) has become the fifth biosimilar referencing Avastin (bevacizumab) to be approved in the United States ..read more
AJMC Biosimilars
3M ago
In 2023, adalimumab biosimilars took center stage in the biosimilar space due to 8 long-anticipated products finally launching ..read more
AJMC Biosimilars
4M ago
ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting ..read more
AJMC Biosimilars
4M ago
Patients with inflammatory bowel disease (IBD) receive additional evidence on the safety and efficacy of adalimumab biosimilar GP2017 treatment ..read more
AJMC Biosimilars
4M ago
The government of Australia’s pricing policy links the price of new medications with similar safety and efficacy, resulting in significant savings over the first 3 years after the etanercept biosimilar Brenzys was introduced ..read more
AJMC Biosimilars
4M ago
As part of updates to its standard formulary, CVS Caremark has removed Amjevita and now prefers Hyrimoz and an unbranded biosimilar ..read more
AJMC Biosimilars
4M ago
A mandatory nationwide transition from reference adalimumab to a biosimilar was implemented in New Zealand ..read more
AJMC Biosimilars
5M ago
HADLIMA is currently indicated for psoriatic arthritis, plaque psoriasis, and hidradenitis suppurativa, among others ..read more
AJMC Biosimilars
5M ago
A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model ..read more